KR20220065719A - 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 - Google Patents
치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 Download PDFInfo
- Publication number
- KR20220065719A KR20220065719A KR1020210156861A KR20210156861A KR20220065719A KR 20220065719 A KR20220065719 A KR 20220065719A KR 1020210156861 A KR1020210156861 A KR 1020210156861A KR 20210156861 A KR20210156861 A KR 20210156861A KR 20220065719 A KR20220065719 A KR 20220065719A
- Authority
- KR
- South Korea
- Prior art keywords
- fusion protein
- enzyme
- pharmaceutical composition
- region
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152247 | 2020-11-13 | ||
| KR1020200152247 | 2020-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220065719A true KR20220065719A (ko) | 2022-05-20 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210156861A Pending KR20220065719A (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4245311A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549323A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220065719A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021378707A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196258A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023006437A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302858A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005580A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022103221A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202304534B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121793950A (zh) * | 2023-09-14 | 2026-04-03 | 株式会社绿十字 | 新的含有α-半乳糖苷酶A融合蛋白的冻干制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| PT2542257T (pt) * | 2010-03-01 | 2017-10-09 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| US12194079B2 (en) * | 2017-01-05 | 2025-01-14 | Protalix Ltd. | Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase |
| US20200157172A1 (en) * | 2017-07-07 | 2020-05-21 | HANMl PHARM. CO., LTD. | Novel therapeutic enzyme fusion protein and use thereof |
| FR3069340A1 (fr) * | 2017-07-21 | 2019-01-25 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| EP3708661A4 (en) * | 2017-12-22 | 2021-12-01 | Hanmi Pharm. Co., Ltd. | THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE |
-
2021
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023549323A (ja) | 2023-11-24 |
| WO2022103221A1 (ko) | 2022-05-19 |
| CN116419760A (zh) | 2023-07-11 |
| CA3196258A1 (en) | 2022-05-19 |
| US20230405093A1 (en) | 2023-12-21 |
| MX2023005580A (es) | 2023-05-29 |
| AU2021378707A1 (en) | 2023-06-01 |
| IL302858A (en) | 2023-07-01 |
| CO2023006437A2 (es) | 2023-06-09 |
| AU2021378707A9 (en) | 2024-07-11 |
| EP4245311A4 (en) | 2024-10-30 |
| EP4245311A1 (en) | 2023-09-20 |
| ZA202304534B (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102712547B1 (ko) | 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도 | |
| US20220118049A1 (en) | Methods for dosing an actriib antagonist and monitoring of treated patients | |
| US20200255495A1 (en) | Antagonists of actriib and uses for increasing red blood cell levels | |
| AU2018200463B2 (en) | ActRIIb antagonists and dosing and uses thereof | |
| AU2016204287B2 (en) | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy | |
| RU2592670C2 (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| CA2729054C (en) | Antagonists of actriib and uses for increasing red blood cell levels | |
| AU2021201185A1 (en) | Methods and compositions for treating ulcers | |
| TW200906849A (en) | Natriuretic fusion proteins | |
| KR20170088927A (ko) | 골수형성이상 증후군 및 철적혈모구 빈혈을 치료하기 위한 방법 | |
| KR102569658B1 (ko) | 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도 | |
| EP4197550A1 (en) | Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors | |
| JP2013533875A (ja) | 免疫グロブリン断片を用いた第7因子(FactorVIIa)薬物結合体 | |
| CN116419760A (zh) | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途 | |
| KR20220065720A (ko) | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도 | |
| US20250161211A1 (en) | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | |
| EA051281B1 (ru) | Применение слитого с терапевтическим ферментом белка для предупреждения и лечения почечного заболевания, вызванного или связанного с болезнью фабри | |
| EA051314B1 (ru) | Применение слитого с терапевтическим ферментом белка для предупреждения и лечения нейропатии, считающейся следствием болезни фабри или ассоциированной с болезнью фабри |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |